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Limited available evidence supports 
theoretical predictions of reduced 
vaccine efficacy at higher exposure 
dose
Kate e. Langwig  1,2, M. Gabriela M. Gomes3,4, Mercedes D. Clark1, Molly Kwitny1, 
Steffany Yamada1, Andrew R. Wargo5 & Marc Lipsitch  2
Understanding the causes of vaccine failure is important for predicting disease dynamics in vaccinated 
populations and planning disease interventions. Pathogen exposure dose and heterogeneity in host 
susceptibility have both been implicated as important factors that may reduce overall vaccine efficacy 
and cause vaccine failure. Here, we explore the effect of pathogen dose and heterogeneity in host 
susceptibility in reducing efficacy of vaccines. Using simulation-based methods, we find that increases 
in pathogen exposure dose decrease vaccine efficacy, but this effect is modified by heterogeneity 
in host susceptibility. In populations where the mode of vaccine action is highly polarized, vaccine 
efficacy decreases more slowly with exposure dose than in populations with less variable protection. 
We compared these theoretical results to empirical estimates from a systematic literature review of 
vaccines tested over multiple exposure doses. We found that few studies (nine of 5,389) tested vaccine 
protection against infection over multiple pathogen challenge doses, with seven studies demonstrating 
a decrease in vaccine efficacy with increasing exposure dose. Our research demonstrates that pathogen 
dose has potential to be an important determinant of vaccine failure, although the limited empirical 
data highlight a need for additional studies to test theoretical predictions on the plausibility of reduced 
host susceptibility and high pathogen dose as mechanisms responsible for reduced vaccine efficacy in 
high transmission settings.
Measurements of vaccine efficacy frequently vary across transmission settings, which limits generalizability of 
results from preclinical experiments and clinical trials. For example, efficacy of the RTS/S malaria vaccine varies 
dramatically among location (e.g. 17% efficacy in Burkina Faso to 66% in Kilifi, Kenya)1. Differences in expo-
sure risk among individuals likely contribute to observed differences in vaccine efficacy among clinical trials2. 
Differences in exposure dose affect disease risk, and high doses of pathogens increase the probability of infection 
in most host-pathogen systems3. However, the relationship between pathogen dose and vaccine efficacy is less 
clear, and few studies have tested vaccines across a broad range of pathogen doses4–10, notwithstanding the belief 
that vaccines may be overcome at high rates of exposure11.
Differences in susceptibility among and within populations also affect risk, thus influencing measurements of 
vaccine efficacy. Here, we define ‘susceptibility’ as the probability of infection per unit of exposure. Myriad factors 
may affect susceptibility including age, nutritional status, or infection with other parasites12. Effective vaccines 
should reduce mean susceptibility thereby decreasing the probability hosts become infected. However, in addition 
to reducing mean susceptibility, vaccines may also change variance in susceptibility, dependent on the mode of 
vaccine action, which could further influence population measures of vaccine efficacy.
The mode of vaccine action, or the shape and variance of susceptibility, can influence disease dynamics, 
and is therefore important to consider in assessing spread and transmission of pathogens through vaccinated 
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populations10,13. Vaccines that have highly polarized modes of action have been termed “all-or-nothing” because 
hosts are practically either completely protected or unprotected following vaccination. Modes of vaccine action 
that are less polarized are termed “leaky”, and in the most extreme instance, partially protect each host to an 
identical degree. In randomized vaccine trials, the distribution of pathogen exposure dose should be balanced by 
randomization between the vaccinated and control groups. However, the distribution (mean, variance and higher 
moments) may differ between these groups, while within a group there will be varying levels of pathogen expo-
sure dose10. Here, we examine the impact of variance in susceptibility in vaccinated and unvaccinated individuals 
on vaccine efficacy across escalating pathogen doses.
Methods
We examined the influence of exposure dose and heterogeneity in susceptibility on vaccine efficacy. We first 
sampled susceptibility of a host population from a beta distribution with a mean susceptibility of 0.18 for the 
vaccinated group, and 0.9 for the unvaccinated (control) group, arbitrarily assuming a total number enrolled in 
the trial of 140,000 (70,000 in each arm). Mean susceptibility values were selected to obtain 80% efficacy at the 
limit of a low exposure-dose, with a visible decline over the range of doses considered. We then selected a group 
of 10,000 individuals from both the vaccinated and control groups to challenge at a given dose. From this, we 
calculated the probability of each individual becoming infected at a given dose using 1 – exp(-dose*susceptibil-
ity), where both dose and susceptibility were continuous variables. We performed this simulation for nine differ-
ent susceptibility shape combinations, with variance ranging from 0.09 (polarized beta distribution) to 9 × 10−7 
(homogenous distribution where nearly every individual had a susceptibility equal to the mean). We then took 
the mean probability of infection for each dose and estimated vaccine efficacy at each using 1 – Risk Ratio (the 
probability of infection in the vaccine group divided by the probability of infection in control group). Under this 
model, the probability of becoming infected depends only on susceptibility and the total exposure dose, and 
therefore exposure could be considered as either dose during a single exposure, or the total number of exposures 
of fixed or varying dosage.
We compared our results with published estimates of vaccine efficacy obtained from controlled challenge 
studies based on a systematic literature review using keywords (dose AND vaccine efficacy) OR (dose AND 
vaccine probability) in PubMed (Fig. S1). Two observers screened the PubMed results, and we restricted our 
comparisons to studies where vaccinees (vaccinated individuals) and an unvaccinated control group were tested 
against multiple pathogen doses in the same study, and sample sizes were greater than 2 individuals per group. 
We also identified several additional studies meeting our criteria based on reviews of reference sections of iden-
tified articles. Several studies we identified also varied vaccine dosage, and in cases where vaccine dose did not 
significantly influence vaccine protection, we combined data among treatment groups. In all other instances, we 
calculated vaccine efficacy of the most efficacious vaccine type at the most efficacious vaccine dose reported in 
each study. We analyzed the effect of pathogen dose on vaccine efficacy using a generalized linear mixed model 
with a binomial distribution and a logit link with disease as a random effect and treatment group interacting with 
ordinal dose as fixed effects. Statistical models were analyzed using package lme414, and all simulations and anal-
yses were conducted in RStudio v. 1.0.15315.
Study
No. of Challenge 
Doses Study Organism Pathogen Response Variable Citation
Bosseray 1980 5 Mouse Brucella abortus Placental colonization 25
Bublot 2007 6 Chicken H5N1 Influenza Mortality 32
Chernokhaeva 2016 3 Mouse Tick-borne encephalitis virus Infection and Mortality 31
Churcher 2017 4 Mouse Malaria Infection 28
Cronly-Dillon 1972 2 Mouse Salmonella sv. typhimurium Infection 7
Delagrave 2012 4 Mouse Herpes simplex virus Type 2 Mortality 33
Ghiasi 1997 2 Mouse Herpes simplex virus Type 1 Mortality 34
Henry 1966 5 Human Poliovirus Infection 29
Hatch 1964 12 Mouse Francisella (Pasteurella) tularensis Mortality 35
Islam 2007 2 Chicken Mareks Disease virus Infection 5
Marchart 2003 3 Mouse Pasteurella multocida Mortality 8
Miller 2006 2 Duck Duck hepatitus B virus Chronic infection 26
Plotkin 1989 2* Human Human cytomegalovirus Infection 27
Sebunya 1982 3 Mouse Haemophilus pleuropneumoniae Mortality 36
van Loon 2002 3 Chicken Reovirus Isolation from organ 30
Yamashita 2009 2 Sevenband grouper Red-spotted grouper nervous necrosis virus Mortality 37
Table 1. Studies identified as a result of a systematic review of vaccines tested over multiple pathogen challenge 
doses. Inclusion criteria included studies where vaccinees (vaccinated individuals) and an unvaccinated control 
group were tested against multiple pathogen doses in the same study. *Indicates a study in which only two 
pathogen doses were tested for a seronegative participant group, but three doses were tested across vaccinees.
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Results
Simulations showed that vaccine efficacy decreased non-linearly with increasing dose (Fig. 1). As dose increased, 
vaccine efficacy declined most sharply when the susceptibility distributions in the vaccinated group had lower 
variance. At moderate doses, highly polarized susceptibility among vaccinees resulted in the highest estimates of 
vaccine efficacy. At low exposure doses, there was little difference in probability of infection and vaccine efficacy 
if susceptibility was homogeneous or hump-shaped, despite a three orders of magnitude difference in variance. At 
the highest doses, vaccine efficacy was close to 0 for groups with homogeneous or hump-shaped modes of vaccine 
action, whereas vaccine efficacy remained above 40% for polarized distributions. Heterogeneity in susceptibility 
in the control group had little influence on probability of infection and vaccine efficacy because the mean proba-
bility of infection was very high, and no individuals were entirely protected.
Our systematic review highlighted the paucity of studies that have tested vaccines at multiple pathogen doses. 
Our broad search criteria identified 5389 articles (as of March 23 2017). Of these, 253 articles were identified 
for further screening based on information in the abstract, however only 16 studies met the inclusion criteria 
(Table 1). Nine studies used infection or clinical signs as an outcome variable whereas the others used mortality 
(Fig. 2). Nine total studies also tested vaccines across more than two different pathogen doses, but only five of 
these used infection or clinical signs as a response variable.
Empirical estimates showed that increasing pathogen challenge dose decreased infection vaccine efficacy 
(treatment and dose interaction: P < 0.0001), although results varied among studies (random effect of disease: 
Figure 1. Estimates of vaccine efficacy over a range of pathogen doses allowing for variation in heterogeneity 
in susceptibility. (A) Susceptibility distributions of vaccinated and control (unvaccinated) groups used in 
simulation. (B) Estimated probability of infection control (solid lines) and vaccine group (dashed lines) 
+/− standard error of mean. Colors correspond to susceptibility distributions in panel (A). (C) Measurable 
vaccine efficacy decreases with increasing exposure dose despite the constancy in intrinsic efficacy given by the 
susceptibility distributions (intrinsic vaccine efficacy = 0.8). Colors and labels are the vaccine efficacy estimated 
from the corresponding susceptibility distributions in panel (A). Error bars show 95% confidence intervals.
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variance = 3.43). For some diseases that examined vaccine protection across five or more different pathogen chal-
lenge doses (e.g. poliovirus and malaria), vaccine efficacy decreased in accordance with our predictions from the 
simulation. However, for Brucella abortus and reovirus, which used organ colonization as the response variable, 
there was no decrease in vaccine efficacy with increasing pathogen dose. While the overall trend aligned with 
our theoretical predictions, most studies tested a small number of pathogen doses making it difficult to discern 
whether vaccines were truly not overcome at high pathogen challenge doses or whether the doses studied were 
just insufficient to overcome vaccines.
Discussion
Our simulation suggests that estimates of vaccine efficacy should be much lower under high pathogen challenge 
dose regardless of susceptibility heterogeneity. While our review revealed a very small number of studies that 
have tested vaccines across a broad range of pathogen challenge doses, there is some limited empirical evidence 
that data aligns with our theoretical predictions. However, two studies appeared to show no consistent trend 
with dose, and offered hosts complete protection regardless of pathogen dose. Notably, doses of Brucella abortus 
spanned five orders of magnitude, but no vaccinated hosts were colonized across this large dose range. These 
findings suggest that these vaccines drastically reduce susceptibility above the range tested in our simulation and 
highlight a need for additional experiments testing highly efficacious vaccines over multiple pathogen doses.
Additional dose-ranging challenge studies would be useful in that they can be used to both assess vaccine 
efficacy2,16 and estimate heterogeneity in host susceptibility10,13. These estimates of host heterogeneity can be 
incorporated into dynamical models to improve predictions of pathogen spread in vaccinated populations10, and 
Figure 2. The fraction of individuals infected (A) and estimates of vaccine efficacy (B) for Brucella abortus in 
mice (H.38 B. melitensis killed vaccine25), duck hepatitis b virus in ducks (duck hepatitis b virus surface protein 
DNA vaccine26), Human cytomegalovirus in humans (Towne cytomegalovirus vaccine27), malaria in mice 
(anti-circumsporozoite protein, efficacy estimated from total residual sporozoite scores across all bites binned 
across groups for visualization28), Marek’s disease in broiler chickens (turkey herpesvirus vaccine5), poliovirus 
in human infants (oral poliovirus vaccine29), reovirus in chickens (attenuated reovirus vaccine30), Salmonella 
typhimurium in mice (heat-killed S. typhimurium vaccine7), and tick-borne encephalitis in mice (tick-borne 
encephalitis vaccine31).
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also account for the apparent reductions in vaccine efficacy over time in clinical trials2. While human-challenge 
studies are ethically controversial and only appropriate for some pathogens, animal systems can still provide 
important insights about the failure of vaccines to protect individuals in high transmission settings, and our 
review suggests that there is opportunity to rapidly expand theory given the limited data on this topic17. While 
extrapolation to human systems should be done with care, these studies would help to increase the fundamental 
understanding of the relationship between host susceptibility, pathogen dose, and vaccine failure.
Across pathogen species and strains, previous studies have noted that pathogens with higher virulence have 
lower infective doses, suggesting the potential for interactions between low-dose vaccine efficacy and pathogen 
virulence18,19. While our study examined vaccine efficacy within pathogen species and strains, future work could 
examine similar relationships across pathogen strains to assess whether vaccine protection is higher at low doses 
regardless of strain virulence. If vaccines block low dose challenges in both virulent and avirulent strains, this may 
influence strain competition and pathogen evolution20. However, experiments including clinical trials involving 
infections that are not always symptomatic (thus in which some infections may go undetected) can produce 
biased results, and it will be important to design such studies carefully to avoid conflating differences in efficacy 
with differences in the proportion of infections that are detected21.
Although our simulation showed that increasing pathogen challenge dose decreased vaccine efficacy, variance 
in susceptibility also affected vaccine protection. When the mode of vaccine action was polarized (e.g. approach-
ing “all-or-nothing”), vaccine protection decayed more slowly with increasing dose. Similar results are expected 
if exposure accumulates over time and 1 – Rate Ratio is used as the measure of vaccine efficacy16. Interestingly, 
vaccine protection was similar when distributions of susceptibility were both homogeneous and hump-shaped. 
The larger change in vaccine protection when susceptibility distributions were highly polarized is likely a con-
sequence of the inclusion of numerous individuals of very low (near 0) susceptibility. Nonetheless, the mode of 
vaccine action is frequently poorly understood but often assumed to be bimodal, and our results underscore the 
importance of heterogeneity in susceptibility in influencing vaccine efficacy, particularly in high exposure set-
tings. Understanding the distribution of vaccine protection, rather than just the mean level, can help to improve 
predictions of vaccine efficacy in heterogeneous populations10.
Studies often speculate about the potential for vaccine failure at high pathogen doses11,22, yet prior to this 
study, there appears to be little empirical or theoretical basis for this claim. Our results highlight a theoretical basis 
and some empirical evidence for reductions in vaccine efficacy at high exposure doses, and also reveal the strong 
potential for heterogeneity in susceptibility to influence vaccine efficacy. Differences in host susceptibility, as have 
been noted in recent studies on influenza23 and mumps24, can explain age-stratified infection dynamics or disease 
resurgence that is often attributed to vaccine failure. As both pathogen dose and host susceptibility likely play 
important roles in disease dynamics in vaccinated populations, disentangling these effects should be an important 
priority in predicting the public health impact of vaccination programs.
Data Availability
All data files are referenced in the manuscript in Table 1 and Fig. 2. Data within those files is available on https://
github.com/klangwig/vaccineANDpathogen_dose.
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